AEterna Zentaris (STU:ET80) Total Tax Payable : €0.16 Mil (As of Mar. 2024)

View and export this data going back to 1995. Start your Free Trial

What is AEterna Zentaris Total Tax Payable?

AEterna Zentaris's Total Tax Payable for the quarter that ended in Mar. 2024 was €0.16 Mil.

AEterna Zentaris's quarterly Total Tax Payable increased from Sep. 2023 (€0.10 Mil) to Dec. 2023 (€0.17 Mil) but then declined from Dec. 2023 (€0.17 Mil) to Mar. 2024 (€0.16 Mil).

AEterna Zentaris's annual Total Tax Payable increased from Dec. 2021 (€0.16 Mil) to Dec. 2022 (€0.17 Mil) and increased from Dec. 2022 (€0.17 Mil) to Dec. 2023 (€0.17 Mil).

AEterna Zentaris Total Tax Payable Historical Data

The historical data trend for AEterna Zentaris's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Total Tax Payable Chart

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Tax Payable

Get a 7-Day Free Trial

1.30

0.10

0.16

0.17

AEterna Zentaris Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Tax Payable	Get a 7-Day Free Trial															0.10	0.10	0.10	0.17	0.16

AEterna Zentaris Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

AEterna Zentaris Total Tax Payable Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (STU:ET80) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (STU:ET80) » Definitions » Total Tax Payable

Comparable Companies

Traded in Other Exchanges

AEZS:USA AEZS:Canada

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.

AEterna Zentaris (STU:ET80) Headlines

No Headlines